PCVX – Vaxcyte, Inc.
Float Short %
9.37
Margin Of Safety %
Put/Call OI Ratio
0.75
EPS Next Q Diff
0.03
EPS Last/This Y
-1.51
EPS This/Next Y
-0.91
Price
53.89
Target Price
102.11
Analyst Recom
1.2
Performance Q
27.11
Relative Volume
1.71
Beta
1.32
Ticker: PCVX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | PCVX | 46.99 | 1.37 | 5.78 | 4614 |
| 2025-12-29 | PCVX | 46.56 | 1.39 | 13.94 | 4669 |
| 2025-12-30 | PCVX | 45.4 | 1.52 | 0.80 | 4920 |
| 2025-12-31 | PCVX | 46.13 | 1.52 | 0.01 | 4923 |
| 2026-01-02 | PCVX | 46.49 | 1.41 | 1.08 | 5081 |
| 2026-01-05 | PCVX | 46 | 1.41 | 0.40 | 5103 |
| 2026-01-06 | PCVX | 44.83 | 1.28 | 70.00 | 5259 |
| 2026-01-07 | PCVX | 46.11 | 1.27 | 0.90 | 5232 |
| 2026-01-08 | PCVX | 45.34 | 1.21 | 30.00 | 5344 |
| 2026-01-09 | PCVX | 46.09 | 1.26 | 22.50 | 5467 |
| 2026-01-12 | PCVX | 45.87 | 1.26 | 2.35 | 5475 |
| 2026-01-13 | PCVX | 46.02 | 1.27 | 2.00 | 5457 |
| 2026-01-14 | PCVX | 48.49 | 1.27 | 2.40 | 5458 |
| 2026-01-15 | PCVX | 48.03 | 1.27 | 0.60 | 5500 |
| 2026-01-16 | PCVX | 46.58 | 1.27 | 1.43 | 5501 |
| 2026-01-20 | PCVX | 47.52 | 1.24 | 0.49 | 4847 |
| 2026-01-21 | PCVX | 50.23 | 1.22 | 0.00 | 4904 |
| 2026-01-22 | PCVX | 53.89 | 0.75 | 0.12 | 6301 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | PCVX | 47.00 | -42.3 | - | -5.31 |
| 2025-12-29 | PCVX | 46.57 | -42.3 | - | -5.31 |
| 2025-12-30 | PCVX | 45.38 | -42.3 | - | -5.31 |
| 2025-12-31 | PCVX | 46.13 | -42.3 | - | -5.31 |
| 2026-01-02 | PCVX | 46.49 | -42.3 | - | -5.31 |
| 2026-01-05 | PCVX | 46.01 | -42.3 | - | -5.31 |
| 2026-01-06 | PCVX | 44.85 | -42.3 | - | -5.31 |
| 2026-01-07 | PCVX | 46.07 | -42.3 | - | -5.31 |
| 2026-01-08 | PCVX | 45.33 | -42.3 | - | -5.31 |
| 2026-01-09 | PCVX | 46.06 | -42.3 | - | -5.31 |
| 2026-01-12 | PCVX | 45.82 | -42.3 | - | -5.31 |
| 2026-01-13 | PCVX | 46.01 | -42.3 | - | -5.31 |
| 2026-01-14 | PCVX | 48.49 | -42.3 | - | -5.31 |
| 2026-01-15 | PCVX | 48.06 | -42.3 | - | -5.31 |
| 2026-01-16 | PCVX | 46.58 | -42.3 | - | -5.31 |
| 2026-01-20 | PCVX | 47.53 | -42.3 | - | -5.31 |
| 2026-01-21 | PCVX | 50.16 | -42.3 | - | -5.31 |
| 2026-01-22 | PCVX | 53.89 | -42.3 | - | -5.31 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | PCVX | 0.00 | -3.90 | 8.53 |
| 2025-12-29 | PCVX | 0.00 | -3.90 | 8.53 |
| 2025-12-30 | PCVX | -0.29 | -3.90 | 8.53 |
| 2025-12-31 | PCVX | -0.29 | -3.90 | 8.53 |
| 2026-01-02 | PCVX | -0.54 | -3.90 | 8.53 |
| 2026-01-05 | PCVX | -0.54 | -3.94 | 8.53 |
| 2026-01-06 | PCVX | -0.54 | -3.94 | 8.53 |
| 2026-01-07 | PCVX | -0.54 | -3.94 | 8.53 |
| 2026-01-08 | PCVX | -0.54 | -3.94 | 8.53 |
| 2026-01-09 | PCVX | -0.54 | -3.94 | 8.53 |
| 2026-01-12 | PCVX | -0.55 | -3.93 | 8.53 |
| 2026-01-13 | PCVX | -0.54 | -3.93 | 9.38 |
| 2026-01-14 | PCVX | -0.54 | -3.93 | 9.38 |
| 2026-01-15 | PCVX | -0.54 | -3.93 | 9.38 |
| 2026-01-16 | PCVX | -0.54 | -3.93 | 9.38 |
| 2026-01-20 | PCVX | -0.54 | -3.80 | 9.38 |
| 2026-01-21 | PCVX | -0.54 | -3.80 | 9.38 |
| 2026-01-22 | PCVX | -0.54 | -3.80 | 9.37 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.56
Avg. EPS Est. Current Quarter
-1.45
Avg. EPS Est. Next Quarter
-1.53
Insider Transactions
-0.54
Institutional Transactions
-3.8
Beta
1.32
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
12
Fair Value
Quality Score
10
Growth Score
18
Sentiment Score
46
Actual DrawDown %
55.5
Max Drawdown 5-Year %
-76.2
Target Price
102.11
P/E
Forward P/E
PEG
P/S
P/B
2.42
P/Free Cash Flow
EPS
-4.92
Average EPS Est. Cur. Y
-5.31
EPS Next Y. (Est.)
-6.22
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.71
Return on Equity vs Sector %
-50
Return on Equity vs Industry %
-34.1
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Vaxcyte, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 414
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
stock quote shares PCVX – Vaxcyte, Inc. Stock Price stock today
news today PCVX – Vaxcyte, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PCVX – Vaxcyte, Inc. yahoo finance google finance
stock history PCVX – Vaxcyte, Inc. invest stock market
stock prices PCVX premarket after hours
ticker PCVX fair value insiders trading